TransCode Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 3336.4%.

Top 19 shareholders own 11.67% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
9.94%	3i Fund	1,716,600	US$805.1k	0%	13.05%
0.43%	UBS Asset Management AG	74,924	US$35.1k	0%	no data
0.29%	Sheets Smith Wealth Management	50,138	US$23.5k	149%	no data
0.22%	Geode Capital Management, LLC	38,398	US$18.0k	2,840%	no data
0.15%	Citadel Advisors LLC	25,512	US$12.0k	0%	no data
0.14%	Susquehanna International Group, LLP, Asset Management Arm	24,253	US$11.4k	0%	no data
0.11%	Virtu Financial LLC, Asset Management Arm	18,358	US$8.6k	-66.8%	no data
0.1%	Private Capital Management, LLC	17,518	US$8.2k	0%	no data
0.074%	Two Sigma Securities, LLC, Asset Management Arm	12,854	US$6.0k	-41.5%	no data
0.065%	CapFinancial Partners, LLC, Asset Management Arm	11,250	US$5.3k	0%	no data
0.058%	Morgan Stanley, Investment Banking and Brokerage Investments	10,000	US$4.7k	0%	no data
0.046%	Tower Research Capital Europe Limited	7,873	US$3.7k	59.8%	no data
0.026%	Robert Dudley	4,507	US$2.1k	3,890%	no data
0.0081%	Thomas Fitzgerald	1,408	US$660.0	0%	no data
0.0058%	Financial Network Wealth Advisors LLC	1,000	US$468.9	0%	no data
0.0038%	The Lind Partners, LLC	657	US$308.5	0%	no data
0.00093%	Philippe Calais	160	US$75.3	0%	no data
0.00032%	Bank of America Corporation, Asset Management Arm	55	US$25.9	0%	no data
0.00001%	Royal Bank of Canada, Banking & Securities Investments	1	US$0.8	0%	no data